Iovance Biotherapeutics News

Where Will Iovance Biotherapeutics Stock Be in 5 Years?

The Motley Fool14:44 ET

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting

Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline MelanomaSAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherape

Iovance BiotherapeuticsApr 24 00:00 ET

Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Institutional Investors Lost 5.0% Last Week but Have Benefitted From Longer-term Gains

Key Insights Significantly high institutional ownership implies Iovance Biotherapeutics' stock price is sensitive to their trading actions The top 9 shareholders own 51% of the company Insiders h

Simply Wall StApr 23 13:23 ET

AHN Cancer Institute To Offer Groundbreaking Treatment For Metastatic Melanoma; The One-Time Treatment, Made By Iovance Biotherapeutics, Is The First FDA-Approved T-Cell Therapy For Solid Tumors

Allegheny Health Network (AHN) Cancer Institute has become the first health care system in Western Pennsylvania to offer a first-of-its-kind cellular therapy recently approved by the U.S. Food and Dru

BenzingaApr 22 08:49 ET

Exelixis Slips as Barclays Downgrades on Lack of Catalysts

Seeking AlphaApr 11 10:10 ET

Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Yahoo FinanceApr 9 07:56 ET

Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why

Yahoo FinanceApr 8 13:51 ET

Better Growth Biotech Buy: Iovance Biotherapeutics Vs CRISPR Therapeutics

The Motley FoolApr 5 05:03 ET

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

Yahoo FinanceMar 29 11:30 ET

Iovance Biotherapeutics (NASDAQ:IOVA) Pulls Back 5.6% This Week, but Still Delivers Shareholders Impressive 113% Return Over 1 Year

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shareholders might be concerned after seeing the share price drop 15% in the last month. But that doesn't change the fact that the returns over the last

Simply Wall StMar 28 06:13 ET

2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street

Yahoo FinanceMar 26 04:11 ET

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and deliv

Iovance BiotherapeuticsMar 22 00:00 ET

Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Coya Therapeutics, Inc. (COYA) and Iovance Biotherapeutics (IOVA)

TipRanksMar 20 06:01 ET

10 Health Care Stocks With Whale Alerts In Today's Session

Traders often look for circumstances when the market estimation of an option diverges away from its normal worth.

BenzingaMar 19 13:35 ET

Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead

Yahoo FinanceMar 18 02:00 ET

Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks

Yahoo FinanceMar 15 08:18 ET

Express News | Piper Sandler Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19

Moomoo 24/7Mar 14 10:26 ET

Iovance Biotherapeutics (IOVA) Gets a Buy From Piper Sandler

TipRanksMar 14 07:06 ET

Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics

Investors with a lot of money to spend have taken a bearish stance on Iovance Biotherapeutics (NASDAQ:IOVA).And retail traders should know.We noticed this today when the trades showed up on publicly a

BenzingaMar 13 12:16 ET

Iovance Biotherapeutics Is Maintained at Buy by Truist Securities

Iovance Biotherapeutics Is Maintained at Buy by Truist Securities

Dow JonesMar 7 12:05 ET